A FIH Study of YH35324 in Atopic Healthy Subjects or Subjects With Mild Allergic Diseases
Status:
Recruiting
Trial end date:
2022-12-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, PK, and PD following
subcutaneous injections of YH35324 in atopic healthy subjects or adult subjects with mild
allergic diseases. Eligible subjects will be randomized to the YH35324 group, the placebo
group, or the omalizumab group.